Publications
862
Citations
38,442
Est. group size
—
Recurring co-author estimate
Active years
43
Publishing since 1984
Typically publishes in teams of ~15 · 5% small-team papers (≤3 authors) · across 75 venues
- Abstract 7637: Genome-wide CRISPR screening reveals a PKA-driven resistance mechanism to metformin for oral cancer prevention that can be exploited by combination with NSAIDs
Cancer Research · 2026
- Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
Journal of Clinical Oncology · 2025
- Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Journal for ImmunoTherapy of Cancer · 2025
- Development and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid cancer treated with immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer · 2025
- Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs
Cancer Prevention Research · 2025
- The spontaneous neoantigen-specific CD4 <sup>+</sup> T-cell response to a growing tumor is functionally and phenotypically diverse
Journal for ImmunoTherapy of Cancer · 2025
- Pathologic response to neoadjuvant sequenced, lymphatic-sparing SBRT plus pembrolizumab in HPV-negative head and neck squamous cell carcinoma.
Journal of Clinical Oncology · 2025
- The spontaneous neoantigen-specific CD4 <sup>+</sup> T cell response to a growing tumor is functionally and phenotypically diverse
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Abstract 3389: Genetic and clinical landscape of NUTM1 structural variants
Cancer Research · 2025
- Neoadjuvant SBRT followed by evorpacept and pembrolizumab in HPV-mediated head and neck squamous cell carcinoma: Investigation of pathologic response.
Journal of Clinical Oncology · 2025
- Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA- and machine learning–based patient classifier.
Journal of Clinical Oncology · 2025
- A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
UNC Libraries · 2025
- 133 MAIT cell abundance within solid tumors is associated with key clinical characteristics
Regular and Young Investigator Award Abstracts · 2025
- 124 A platform to identify tumor-specific neoantigens and corresponding T cell receptors
Regular and Young Investigator Award Abstracts · 2025
- 157 A novel multi-omic algorithm to predict real-world outcomes among patients with rare, advanced, solid cancers treated with off-label immune checkpoint inhibitors
Regular and Young Investigator Award Abstracts · 2025
- Journal of Clinical Oncology×51
- Annals of Oncology×32
- International Journal of Radiation Oncology*Biology*Physics×26
- Regular and Young Investigator Award Abstracts×19
- Clinical Cancer Research×14
- Darrion Mitchell
Medicine · The Ohio State University
- Marcelo Bonomi
Medicine · The Ohio State University
- Lingbin Meng
Medicine · The Ohio State University
- Priyanka Bhateja
Medicine · The Ohio State University
- Vidhya Karivedu
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile